Position TitleAssociate Professor
Dr. Sosne received his MD at the Albert Einstein College of Medicine, Bronx, NY, and completed a fellowship through the Howard Hughes Medical Institute, Chevy Chase, MD. He then completed his ophthalmology residency at Henry Ford Hospital, Detroit, MI and a fellowship at the National Institutes of Health. He is Board Certified by the American Board of Ophthalmology and is affiliated with the Association of Research and Vision in Ophthalmology and the American Academy of Ophthalmology. Dr. Sosne, a clinician scientist, has a joint appointment as Associate Professor in Ophthalmology, Visual and Anatomical Sciences at Wayne State University School of Medicine. He practices comprehensive ophthalmology at the Kresge Eye Institute with a focus on cataract surgery, corneal and ocular surface wound healing, and dry eye disease. His research interests focused on developing thymosin beta 4 into a novel corneal wound healing agent that suppresses inflammation and promotes tissue survival. Currently, he is studying the wound healing, anti-inflammatory, and anti-apoptosis properties of thymosin beta 4 in Phase II and Phase III clinical trials for dry eye disease and neurotrophic corneal ulcers.
Specialty: Cataract, Dry Eye Disease, Comprehensive Ophthalmology Medical
Appointment Locations: Bingham Farms and Detroit
Board Certification: American Board of Ophthalmology
Special Activities: Member, American Academy of Ophthalmology; Member, Association for Research in Vision and Ophthalmology
Awards & Honors
- 2011 AFER/Pfizer Ophthalmics Carl Camras Translational Research Award, ARVO, May 1, 2011, Fort Lauderdale, FL.
- 2012 Voted to Top Doctors Metro Detroit
- 2012 Top Ophthalmologist, International Association of Ophthalmologists
- 2013 Voted to Best Doctors of America
- 2014 Voted to Best Doctors of America
- Medical: Albert Einstein College of Medicine, Yeshiva University
- Residency: Ophthalmology, Henry Ford Hospital, Detroit, Michigan
- Fellowship: National Institutes of Health, Bethesda, MD
Areas of Research
Developing thymosin beta 4 as a novel therapy for corneal wound healing, inflammation, and dry eye disease
Clinical Interests: Cataract surgery, dry eye diease, diabetic eye exams, macular degeneration, inflammatory eye diseases, glaucoma, external eye diseases
Links of Interest
- Sosne G, Qiu P, Ousler GW 3rd, Dunn SP, Crockford D. Thymosin β4: a potential novel dry eye therapy. Ann N Y Acad Sci. 2012 Oct;1270:45-50. doi: 10.1111/j.1749-6632.2012.06682.x.
- Goldstein, AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: A Multi-Functional Regenerative Peptide Basic Properties and Clinical Applications. Expert Opin Biol Ther. 2012 Jan;12(1):37-51. Epub 2011 Nov 10.
- Qiu P, Wheater MK, Qiu Y, Sosne G. Thymosin beta 4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J. 2011 Feb 22, [Epub ahead of print]
- Dunn SP, Heidemann DG, Chow CYC, Crockford D, Turjman N, Angel J, Allan CB, and Sosne G. "Treatment of Chronic Non-Healing Neurotrophic Corneal Epithelial Defects with Thymosin 4"
- Ann N Y Acad Sci. 2010 Apr;1194:199-206. Dunn, SP, Heidemann DG, Chow CY, Crockford D, Turjman N,Angel, J, Allan CB, Sosne G. Arch Ophthalmol. Treatment of Chronic Nonhealing
- Neurotrophic Corneal Epithelial Defects With Thymosin Beta 4. 2010 May; 128(5):636-8. Sosne G, Qiu P, Goldstein AL, Wheater MK. Biological activities of thymosin beta 4 defined by active sites in short peptide sequences. FASEB J. 2010 Jul;24(7):2144-51. Epub 2010 Feb 23. Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal
- NFkappaB: A potential anti-inflammatory pathway. Exp Eye Res. 2007 Apr;84(4):663-9. Gabriel Sosne, M.D.